Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at approximately $10,133,012.96. This trade represents a 2.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Claire Mazumdar also recently made the following trade(s):
- On Friday, July 10th, Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.42, for a total transaction of $284,200.00.
Bicara Therapeutics Stock Performance
BCAX stock opened at $23.63 on Friday. The company’s fifty day moving average price is $26.06 and its 200-day moving average price is $21.79. Bicara Therapeutics Inc. has a one year low of $10.30 and a one year high of $30.99. The company has a market capitalization of $1.56 billion, a PE ratio of -7.62 and a beta of -0.75.
Key Stories Impacting Bicara Therapeutics
Here are the key news stories impacting Bicara Therapeutics this week:
- Positive Sentiment: Management said enrollment for the pivotal study of ficerafusp alfa remains on track for 2026. Progress toward this milestone could provide an important catalyst for the clinical-stage biotechnology company. Bicara Therapeutics cancer study remains on track
- Positive Sentiment: Analysts raised several price targets following the quarterly results. BTIG increased its target from $28 to $39 and retained a Buy rating, while Morgan Stanley raised its target to $39 with an Overweight rating. The reported consensus view remains Moderately Buy-rated, with an average target near $32.73. Analysts raise Bicara forecasts
- Neutral Sentiment: Bicara reported a second-quarter loss of $0.82 per share, matching the consensus estimate. The result did not provide a major earnings surprise, leaving clinical execution and upcoming trial milestones as the primary valuation drivers. Bicara Q2 2026 earnings call transcript
- Neutral Sentiment: Wells Fargo raised its price target from $16 to $23 but maintained an Equal Weight rating, highlighting disagreement among analysts about the stock’s risk-reward profile. A reported leadership shake-up also introduces some execution uncertainty as Bicara advances its development programs. Bicara leadership and milestone timeline
- Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep sold a combined 41,250 shares for approximately $1.15 million. The sales were made under pre-arranged Rule 10b5-1 plans, and the executives retained substantial holdings, but the cluster of insider sales can still pressure sentiment.
Institutional Investors Weigh In On Bicara Therapeutics
A number of institutional investors have recently added to or reduced their stakes in BCAX. Legal & General Group Plc grew its stake in Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $45,000. Larson Financial Group LLC boosted its holdings in shares of Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after buying an additional 4,585 shares during the last quarter.
Wall Street Analyst Weigh In
Several analysts recently weighed in on BCAX shares. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. The Goldman Sachs Group boosted their price target on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday. Wells Fargo & Company increased their price objective on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Morgan Stanley lifted their price objective on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.73.
View Our Latest Stock Report on Bicara Therapeutics
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Read More
- Five stocks we like better than Bicara Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
